Losartan Potassium 25mg Tablet (Aidapak) – Label Mixup (2013)
Class II: A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Class II recall indicates potential for temporary health effects.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
LOSARTAN POTASSIUM, Tablet, 25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093736498.
Brand
Aidapak Services, LLC
Lot Codes / Batch Numbers
LOSARTAN POTASSIUM, Tablet, 25 mg has the following codes: Pedigree: AD46312_16, EXP: 5/16/2014.
Products Sold
LOSARTAN POTASSIUM, Tablet, 25 mg has the following codes: Pedigree: AD46312_16, EXP: 5/16/2014.
Aidapak Services, LLC is recalling LOSARTAN POTASSIUM, Tablet, 25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093736498. due to Labeling: Label Mixup: LOSARTAN POTASSIUM, Tablet, 25 mg may have potentially been mislabeled as the following drug: PHYTONADIONE, Tablet, 5 mg, NDC . This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA drug enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Labeling: Label Mixup: LOSARTAN POTASSIUM, Tablet, 25 mg may have potentially been mislabeled as the following drug: PHYTONADIONE, Tablet, 5 mg, NDC 25010040515, Pedigree: AD46312_22, EXP: 4/30/2014.
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm, their healthcare provider, or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticeDistribution
As reported by FDA
AZ, CA, IN, OR, WA
Page updated: Jan 7, 2026